Founded September 2017
Stage Technology development
Investors The Trendlines Group, Trendlines Medical Singapore
Contact Project Manager Simon Choe
interVaal is developing UriGuardian, a line of novel Foley catheters with enhanced capability in preventing catheter-associated urinary tract infections (CAUTI), a widespread and costly side-effect of modern health care. UriGuardian’s bio-inspired buffer zone and pressure accumulation feature serves to keep the urethra flushed and to mitigate the migration of bacteria.
With a focus on simple elegance, the interVaal design will not require changes to insertion, maintenance or removal procedures. With high efficacy and reasonable cost, interVaal aims to become the new standard of care globally.
Patent pending
8 years of healthcare experience, including product development, manufacturing, and strategy consulting; 5 years start-up experience
Catheter associated urinary tract infections (CAUTIs) arise from the use of urinary catheters during the course of treatment. In most modern healthcare facilities, CAUTIs are one of the most common infections acquired during treatment. The cost of CAUTI treatment can reach up to $3,000 per episode; in the United States, the total annual cost of CAUTI is over $1 billion.
The leading solution – various advances in catheter coatings – are often ~10 times the cost of a standard catheter but fail to satisfactorily prevent CAUTIs.
